骨骼肌缺血再灌注损伤及发病机制初探

目的：探讨骨骼肌缺血再灌注损伤过程的微循环变化。组织学改变以及多肽含量变化和意义。方法：42只雄性大鼠随机分为留伴行神经组和去伴行神经组,建立标准骨骼肌缺血再灌注模型,采用激光多谱勒及显微放大分析系统,组织学方法以及凝胶电泳方法等观察缺血再灌注损伤变化。结果：缺血再灌注损伤后的骨骼肌微血管管径在20分钟时恢复率基本达到高峰约60％,此后为平台期：90分钟最高峰,为75％,主干血管流速率亦在20分钟基本达到上限,病理检查显示：缺血的骨骼肌纤维呈空泡状,核形态增大,染色加深,红细胞严重聚集,凝胶蛋白电泳提示：缺血骨骼肌中分子量20KD左右的多肽显著增加。结论：骨骼肌缺血再灌注损伤发生后,骨骼肌的微循环发生不同程度的破坏,及因之导致骨骼结构损伤和异常的20KD多肽含量明显增加,以及红细胞凝聚,白细胞的改变,这些共同构成了缺血再灌注损伤机制。     

Electron microscopic evidence of persistent chlamydial infection following treatment

Chlamydia trachomatis infections of the female and male genital tracts are often asymptomatic and, thus, tend to become persistent. In the persistent state the typical Chlamydia life cycle is arrested and standard antibiotic regimens do not always eradicate this infection. We sought to relate treatment failures in men and women with persistent chlamydial genital tract infections to electron microscopic evidence of chlamydial persistence and with atypical morphological forms of the organism. Of 16 patients with chlamydial persistence following azithromycin treatment, morphological variants of this organism were observed by electron microscopy from one endocervical sample and one male urethral sample. We document the presence of intracellular inclusions containing only reticulate bodies, extracellular monomembrane and polymembrane phagosomes containing elementary bodies and reticulate bodies with abnormal outer membranes in the process of dividing extracellularly. These observations parallel previous in vitro studies of chlamydial persistence under adverse conditions. This capacity of C. trachomatis to undergo atypical morphological alterations in vivo may contribute to its persistence and relative resistance to antibiotics.     

Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction

OBJECTIVES: This study characterized clinical factors predictive of cardiogenic shock developing after thrombolytic therapy for acute myocardial infarction (AMI). BACKGROUND: Cardiogenic shock remains a common and ominous complication of AMI. By identifying patients at risk of developing shock, preventive measures may be implemented to avert its development. METHODS: We analyzed baseline variables associated with the development of shock after thrombolytic therapy in the Global Utilization of Streptikonase and Tissue-Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. Using a Cox proportional hazards model, we devised a scoring system predicting the risk of shock. This model was then validated in the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO-III) cohort. RESULTS: Shock developed in 1,889 patients a median of 11.6 h after enrollment. The major factors associated with increased adjusted risk of shock were age (chi2 = 285, hazard ratio [95% confidence interval] 1.47 [1.40, 1.53]), systolic blood pressure (chi2 = 280), heart rate (chi2 = 225) and Killip class (chi2 = 161, hazard ratio 1.70 [1.52, 1.90] and 2.95 [2.39, 3.63] for Killip II versus I and Killip III versus I, respectively) upon presentation. Together, these four variables accounted for >85% of the predictive information. These findings were transformed into an algorithm with a validated concordance index of 0.758. Applied to the GUSTO-III cohort, the four variables accounted for > 95% of the predictive information, and the validated concordance index was 0.796. CONCLUSIONS: A scoring system accurately predicts the risk of shock after thrombolytic therapy for AMI based primarily on the patient's age and physical examination on presentation.     

International variation in invasive care of the elderly with acute coronary syndromes.

AIMS: To explore variations in invasive care of the elderly with acute coronary syndromes across international practice. METHODS AND RESULTS: Using combined populations from the SYMPHONY and 2nd SYMPHONY trials, we describe 30-day cardiac catheterization in elderly (> or = 75 years; n = 1794) vs. younger patients (< 75 years; n = 14,043) after multivariable adjustment and by region of enrolment. The use of cardiac catheterization and revascularization were not protocol-specified. Elderly patients (median age 78 years) were more often female and more frequently had hypertension, diabetes, prior myocardial infarction, and prior coronary bypass surgery. Overall, they underwent less cardiac catheterization than younger patients [53 vs. 63%; adjusted OR 0.53 (0.46, 0.60)]. The absolute rate of cardiac catheterization in the elderly varied from 77% (vs. 91% in younger patients) in the US cohort to 27% (vs. 41% in younger patients) in the non-US cohort. Revascularization of elderly who underwent cardiac catheterization was also higher in US than non-US cohorts (71.3 vs. 53.6%). There was a significant interaction between the patient age and the use of catheterization across US and non-US regions of enrolment, as well as differences in the predictors of catheterization in the elderly. Despite these findings, after adjustment, 90-day rates of death and death or myocardial infarction (MI) were not significantly different in elderly who underwent catheterization compared with those who did not. CONCLUSION: Although older age is universally predictive of lower use of cardiac catheterization, marked variation in catheterization of the elderly exists across international practice. Demonstrated differences in patterns of use suggest a lack of consensus regarding optimal use of an invasive strategy in the elderly.     

End-tidal estimates of arterial PCO2 for cardiac output measurement by CO2 rebreathing: A study in patients with cystic fibrosis and healthy controls

We set out to determine the effects of various estimates of arterial PCO₂ (PaCO₂) on calculation of cardiac output (Q) by the indirect Fick (CO₂) method in healthy children and children with cystic fibrosis (CF), and to develop a prediction equation for children for PaCO₂, based on end-tidal PCO₂ (PetCO₂). The study had 3 parts: 1) Twenty-three healthy children exercised lightly and moderately while arterialized capillary blood gases and PetCO₂ were measured simultaneously so that a prediction equation for PaCO₂ could be derived from PetCO₂. Cardiac output was measured by CO₂ rebreathing at each workload; different values for PaCO₂ (measured in arterialized capillary blood, end-tidal, and PaCO₂ derived from the Bohr equation assuming normal dead space) were used to calculate Q; 2) our equation PaCO₂ = 0.647 PetCO₂ + 12.4 was tested prospectively to measure Q in 9 healthy children; and 3) cardiac output based on arterialized capillary PaCO₂ was compared with that based on Jones-corrected PetCO₂ during light and moderate exercise in 16 CF patients whose forced expiratory volume in 1 second (FEV₁) range from normal to 37% predicted. Our results have shown that in health children end tidal based-estimates of PaCO₂ tended to overestimate Q, whereas PaCO₂ values derived by the Bohr equation and assuming normal dead space tended to underestimate Q, compared with Q calculated from directly measured PaCO₂. Our prediction equation resulted in good agreement compared with directly measured PaCO₂ when used to calculate Q (mean difference, +1.3%; range, +9% to −13%). CF patients with little or no airway obstruction had results similar to healthy controls, but those with severe airway obstruction had lower values for Q when PetCO₂ was used instead of directly measured PaCO₂. We conclude that estimates of PaCO₂ from PetCO₂ are not reliable in patients with moderately severe pulmonary disease due to CF. In healthy children, the prediction equation for PaCO₂ from PetCO₂ derived in the present study gives results superior to other bloodless methods currently in use for computation of Q by the indirect Fick (CO₂) method. Pediatr Pulmonol. 1996; 22:154–160. © 1996 Wiley-Liss, Inc.